NFKB1 and relapsing-remitting multiple sclerosis: Laquinimod (LAQ), a new oral immunomodulatory compound for relapsing and remitting multiple sclerosis (RRMS), can ameliorate myelin injury via down-regulating NF-κB activation in astrocytes rather than in microglia in vivo and in vitro (Brück et al., 2012).